Evidence map›Paper›PMID 32195176›Full record

ArticleFrontiers in oncology2020

Phosphofructokinase 1 Platelet Isoform Promotes β-Catenin Transactivation for Tumor Development.

Jong-Ho Lee, Fei Shao, Jinjie Ling, Sean Lu, Rui Liu, Linyong Du, Jin Woong Chung, Sang Seok Koh, Sun-Hee Leem, Jichun Shao and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  3. Review
  4. mFrontiers in cell and developmental biology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Phosphofructokinase-1 in Cancer: A Promising Target for Diagnosis and Therapy.Recent patents on anti-cancer drug discovery · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. PFKP silencing suppresses tumor growth via the AXL-MET axis.International journal of biological sciences · 2024
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. PFKP: More than phosphofructokinase.Advances in cancer research · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Jong-Ho LeeDepartment of Biological Sciences, Dong-A University, Busan, South Korea.
Fei ShaoCancer Institute of the Affiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Jinjie LingBrain Tumor Center and Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sean LuBrain Tumor Center and Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Rui LiuState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Linyong DuKey Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Jin Woong ChungDepartment of Biological Sciences, Dong-A University, Busan, South Korea.
Sang Seok KohDepartment of Biological Sciences, Dong-A University, Busan, South Korea.
Sun-Hee LeemDepartment of Biological Sciences, Dong-A University, Busan, South Korea.
Jichun ShaoDepartment of Urology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, China.
Dongming XingCancer Institute of the Affiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao, China.
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, United States.
Zhimin LuDepartment of Hepatobiliary and Pancreatic Surgery and Zhejiang Provincial Key Laboratory of Pancreatic Disease of the First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Dong-A University · KRAffiliated Hospital of Qingdao University · CNThe University of Texas MD Anderson Cancer Center · USBrown Foundation · USChina National Nuclear Corporation · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNWenzhou Medical University · CNZhejiang University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Metabolism plays a critical role in direct regulation of a variety of cellular activities via metabolic enzymes and metabolites. Here, we demonstrate that phosphofructokinase 1 platelet isoform (PFKP), which catalyzes a rate-limiting reaction in glycolysis, promotes EGFR activation-induced nuclear translocation and activation of β-catenin, thereby enhancing the expression of its downstream genes

Indexed as

c-Myccyclin D1invasionmigrationPFKPproliferationβ-catenin

Identifiers

PMID32195176
PMCPMC7066116
OpenAlexW3010220091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.